Technology
Adaptive Bioelectronic and Biopharmaceutical Technologies.
Aurealix develops adaptive technology architectures that combine historically learning models, neurocartographic mapping and probabilistic physiological control.
Platform structure
Two pillars.
One adaptive
intelligence core.
The Aurealix technology position is organized around two complementary pillars. The bioelectronic pillar focuses on neurocartography, adaptive neuromodulation and stimulation systems with spatiotemporal activation patterns and response-phase logic. The biopharmaceutical pillar focuses on probabilistic in vivo delivery, proteostasis, tipping points and hazard-function based control.
Pillar I
Bioelectronics and neurocartography.
Adaptive bioelectronic concepts for personalized neuromodulation, multimodal sensing and historically learning functional neurocartography.
- Bioelectronic systems and sensing
- Functional neurocartography
- Spatiotemporal activation patterns
- Response-phase logic and adaptive feedback
Pillar II
Probabilistic biopharmaceutical control.
Probabilistic architectures for adaptive in vivo release, proteostasis instability modelling and tipping-point based therapeutic optimization.
- Probabilistic in vivo delivery
- Adaptive therapeutics
- Proteostasis and tipping-point models
- Hazard functions for release decisions
NSPP
Neurostimulation planning.
Planning logic for personalized stimulation strategies based on mapped responses and adaptive selection.
APIM
Adaptive physiological modelling.
Model structures for interpreting historical physiological signals and updating intervention logic over time.
AFN
Adaptive functional networks.
Functional network concepts for linking measured responses, contextual states and adaptive intervention decisions.
Shared core
Historically learning and probabilistically optimized.
Across both pillars, the common architecture is based on continuous observation, historical model building, uncertainty-aware decision logic, verification of predicted responses and adaptive model updating. The output differs by domain: bioelectronic interaction in MedTech, physiological substance release in Biopharma.
IP position
Patent-pending portfolio.
Aurealix is supported by a portfolio of fifteen patent filings focused on adaptive bioelectronic systems, neurocartographic knowledge models, probabilistic physiological control and adaptive therapeutic architectures.
Collaboration
Validation partners welcome.
Aurealix is seeking dialogue with academic, clinical, technology and industrial partners interested in validation, platform development and translational pathways.